148 results
424B3
KZIA
Kazia Therapeutics Limited
27 Mar 24
Prospectus supplement
8:37am
to recruitment in Canada. Expansion to several countries in Europe was completed during CY2022. Final data from the GBM AGILE study is anticipated during 1H … stage of the GBM AGILE study, and that recruitment had therefore completed with approximately 150 patients enrolled to the first stage. Those patients
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
27 Mar 24
Current report (foreign)
8:26am
, the study opened to recruitment in Canada. Expansion to several countries in Europe was completed during CY2022. Final data from the GBM AGILE study … not graduated to the second stage of the GBM AGILE study, and that recruitment had therefore completed with approximately 150 patients enrolled
424B3
KZIA
Kazia Therapeutics Limited
5 Feb 24
Prospectus supplement
4:19pm
, which we licensed from Evotec SE in April 2021. In November 2021, we commenced recruitment to a phase I, first-in-human, multiple-ascending-dose
F-1
KZIA
Kazia Therapeutics Limited
31 Jan 24
Registration statement (foreign)
12:00am
of vascular endothelial growth factor receptor 3, which we licensed from Evotec SE in April 2021. In November 2021, we commenced recruitment to a phase I
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
18 Jan 24
Current report (foreign)
4:30pm
of synergy with immuno-oncology agents. A Phase I study in advanced solid tumors commenced recruitment in November 2021.
For more information, please
F-3
yqmjy8xkcb8x3527 jsd
15 Dec 23
Shelf registration (foreign)
5:26pm
6-K
EX-99.1
37ciw8
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
424B5
j0t iuhermedqb3h18
4 Dec 23
Prospectus supplement for primary offering
4:05pm
6-K
EX-99.1
kyt28h vw2wzpc
1 Dec 23
Kazia Therapeutics Announces $2 Million Registered Direct Offering
8:30am
6-K
EX-99.1
w74 bpxjxv
29 Nov 23
Kazia Announces Non-binding Letter of
4:19pm
6-K
EX-99.1
1szdrou qxs6
21 Nov 23
Current report (foreign)
4:09pm
6-K
EX-99.1
bgx v3evcy2
20 Nov 23
Kazia Announces Receipt of Nasdaq Minimum Bid Notification
4:39pm
6-K
EX-99.1
9jhl1c
15 Nov 23
Kazia Announces the Release of PNOC022
9:13am
6-K
EX-99.1
6h75 z1f6e6m
14 Nov 23
Kazia Announces Publication In Molecular
12:00am
6-K
EX-99.1
11edt89yddouj1ia6jni
1 Nov 23
Kazia Therapeutics Provides Preliminary Update
4:17pm
6-K
EX-99.1
r9j70 4993v
23 Oct 23
Kazia Therapeutics Announces Clinical Data at Esmo 2023 from Ongoing Phase 1 EVT801 Study
8:30am
6-K
EX-99.1
7payt skf7psa7
13 Oct 23
Current report (foreign)
4:08pm
6-K
EX-99.1
1eb6gp4
11 Oct 23
Kazia Announces Voluntary Delisting from Asx
7:35am
6-K
EX-99.1
kko9q4yh4y3 bk
10 Oct 23
Current report (foreign)
3:04pm